Arbiter Partners Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Arbiter Partners Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-193,124	Closed	-$608K	–	55
2020 Q1	$608K	Sell	193,124 -654,945	-77%	-$2.42M	0.09%	28
2019 Q4	$3.42M	Sell	848,069 -258,353	-23%	-$896K	0.5%	12
2019 Q3	$4.78M	Hold	1,106,422	–	–	0.87%	15
2019 Q2	$4.42M	Hold	1,106,422	–	–	0.86%	15
2019 Q1	$5.93M	Sell	1,106,422 -5,514	-0.5%	-$35.6K	1.2%	14
2018 Q4	$5.7M	Buy	1,111,936 +119,790	+12%	+$910K	0.64%	19
2018 Q3	$9.62M	Buy	992,146 +215,837	+28%	+$2.18M	0.96%	13
2018 Q2	$7.92M	Buy	776,309 +682,959	+732%	+$7.73M	0.79%	18
2018 Q1	$1.21M	Buy	+93,350	New	+$1.39M	0.15%	40

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arbiter Partners Capital Management's PRTK Position: Q2 2020 in Review

Arbiter Partners Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2020, closing a stake of 193,124 shares — an estimated $608K sold.

Arbiter Partners Capital Management first reported a position in PRTK in Q1 2018 and held it in 9 quarters. The position peaked at $9.62M in Q3 2018. 99 funds tracked by Wall St. Rank hold PRTK as of Q2 2020.

Arbiter Partners Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Arbiter Partners Capital Management sold 193,124 Paratek Pharmaceuticals, Inc. shares in Q2 2020, an estimated $608K.
Arbiter Partners Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and held it in 9 quarters.
Arbiter Partners Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $9.62M in Q3 2018.
99 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2020.

Based on Arbiter Partners Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.